Ergomed - Edison Group

Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Sparks
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

Argent Biopharma

MCap

AUD12m

Last close

AUD0.20

▲ 0.07 (50.00%)

Metals One

MCap

GBP4m

Last close

GBP0.01

▲ 0.18 (19.44%)

The Metals Company

MCap

USD675m

Last close

USD1.95

▲ 0.01 (0.52%)
Sectors
Sectors
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

Financial Director
Equity Research
Investor Relations
Contact us

Overview
Research
Thematics

Latest Insights

View More

Healthcare |
Update

17.04.23

Ergomed — Solid FY22 marked by broad-based growth

Healthcare |
Update

21.12.22

Ergomed — Exiting FY22 on a strong footing

Healthcare |
Flash note

18.11.22

Ergomed — Two key management changes

Healthcare |
Update

30.09.22

Ergomed — Poised for a strong FY22

Update

Healthcare

23.03.21

Ergomed — Transformative 2020; solid fundamentals for 2021

edison tv

Healthcare

03.02.21

Ergomed – Edison Open House interview

Update

Healthcare

26.01.21

Ergomed — PrimeVigilance excels; CRO strengthened in US

Flash note

Healthcare

14.12.20

Ergomed — MedSource acquisition to boost US CRO business

Update

Healthcare

22.09.20

Ergomed — Adj EBITDA upgrade despite industry challenges

edison tv

Healthcare

12.08.20

Ergomed – executive interview

Update

Healthcare

23.07.20

Ergomed — Diversified services offering proves resilient

Flash note

Healthcare

10.06.20

Ergomed — AGM update: ‘Revenue growth trend’ maintained

Initiation

Healthcare

25.03.20

Ergomed — Resilient global pharma services specialist